SJT Molecular Research

SJT Molecular Research is a Spanish biotechnology company focused on the discovery and early development of novel small molecule therapies for metabolic syndrome and associated disorders. The company's core technology centers on a proprietary family of beta-carboline compounds, with the lead candidate SJT4a demonstrating a unique dual mechanism of action as both a 5-HT2A receptor antagonist and a Farnesoid X receptor (FXR) agonist. These molecules are being developed to treat a spectrum of conditions including non-alcoholic steatohepatitis (NASH), obesity, and Type 2 Diabetes. Operating through a virtual model, SJT Molecular Research collaborates with a global network of academic institutions and contract research organizations to advance its pipeline. The company holds a robust international patent portfolio covering its chemical entities and their use in metabolic health.